Tags

Type your tag names separated by a space and hit enter

Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Eur J Nucl Med Mol Imaging. 2016 Feb; 43(2):362-373.EJ

Abstract

In Alzheimer's disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss. Since the advent of the first Aβ-specific positron emission tomography (PET) ligand, (11)C-Pittsburgh compound B ([(11)C]PIB), several (18)F ligands have been developed that circumvent the limitations of [(11)C]PIB tied to its short half-life. To date, three such compounds have been approved for clinical use by the US and European regulatory bodies, including [(18)F]AV-45 ([(18)F]florbetapir; Amyvid™), [(18)F]-BAY94-9172 ([(18)F]florbetaben; Neuraceq™) and [(18)F]3'-F-PIB ([(18)F]flutemetamol; Vizamyl™). The present review aims to summarize and discuss the currently available knowledge on [(18)F]flutemetamol PET. As the (18)F analogue of [(11)C]PIB, [(18)F]flutemetamol may be of use in the differentiation of AD from related neurodegenerative disorders and may help with subject selection and measurement of target engagement in the context of clinical trials testing anti-amyloid therapeutics. We will also discuss its potential use in non-AD amyloidopathies.

Authors+Show Affiliations

Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. kerstin.heurling@radiol.uu.se.Department NVS, Centre for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden.Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul (PUCRS), Porto Alegre, Brazil. Department of Biochemistry, Federal University of Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.Section of Nuclear Medicine and PET, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.Department NVS, Centre for Alzheimer Research, Division of Translational Alzheimer Neurobiology, Karolinska Institutet, Huddinge, Sweden. Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26440450

Citation

Heurling, Kerstin, et al. "Imaging Β-amyloid Using [(18)F]flutemetamol Positron Emission Tomography: From Dosimetry to Clinical Diagnosis." European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, no. 2, 2016, pp. 362-373.
Heurling K, Leuzy A, Zimmer ER, et al. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging. 2016;43(2):362-373.
Heurling, K., Leuzy, A., Zimmer, E. R., Lubberink, M., & Nordberg, A. (2016). Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 43(2), 362-373. https://doi.org/10.1007/s00259-015-3208-1
Heurling K, et al. Imaging Β-amyloid Using [(18)F]flutemetamol Positron Emission Tomography: From Dosimetry to Clinical Diagnosis. Eur J Nucl Med Mol Imaging. 2016;43(2):362-373. PubMed PMID: 26440450.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. AU - Heurling,Kerstin, AU - Leuzy,Antoine, AU - Zimmer,Eduardo R, AU - Lubberink,Mark, AU - Nordberg,Agneta, Y1 - 2015/10/06/ PY - 2015/06/15/received PY - 2015/09/28/accepted PY - 2015/10/7/entrez PY - 2015/10/7/pubmed PY - 2016/10/7/medline KW - Alzheimer’s disease KW - Mild cognitive impairment KW - Positron emission tomography KW - Vizamyl KW - [18F]Flutemetamol KW - β-amyloid SP - 362 EP - 373 JF - European journal of nuclear medicine and molecular imaging JO - Eur J Nucl Med Mol Imaging VL - 43 IS - 2 N2 - In Alzheimer's disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss. Since the advent of the first Aβ-specific positron emission tomography (PET) ligand, (11)C-Pittsburgh compound B ([(11)C]PIB), several (18)F ligands have been developed that circumvent the limitations of [(11)C]PIB tied to its short half-life. To date, three such compounds have been approved for clinical use by the US and European regulatory bodies, including [(18)F]AV-45 ([(18)F]florbetapir; Amyvid™), [(18)F]-BAY94-9172 ([(18)F]florbetaben; Neuraceq™) and [(18)F]3'-F-PIB ([(18)F]flutemetamol; Vizamyl™). The present review aims to summarize and discuss the currently available knowledge on [(18)F]flutemetamol PET. As the (18)F analogue of [(11)C]PIB, [(18)F]flutemetamol may be of use in the differentiation of AD from related neurodegenerative disorders and may help with subject selection and measurement of target engagement in the context of clinical trials testing anti-amyloid therapeutics. We will also discuss its potential use in non-AD amyloidopathies. SN - 1619-7089 UR - https://www.unboundmedicine.com/medline/citation/26440450/Imaging_β_amyloid_using_[_18_F]flutemetamol_positron_emission_tomography:_from_dosimetry_to_clinical_diagnosis_ L2 - https://dx.doi.org/10.1007/s00259-015-3208-1 DB - PRIME DP - Unbound Medicine ER -